Clinical Trials Browser

INDUSTRY × Has results × Thyroid Carcinoma, Anaplastic × Clear all

Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma, Thyroid Carcinoma, Anaplastic

NCT02034110 2023-08-21

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Phase 2 Completed

206 enrolled 40 charts 2 FDA

CNSEndocrineGastrointestinalHead & NeckOther hematologic neoplasmPlasma cellSarcoma

Nonseminomatous germ cell tumor, Biliary Tract Neoplasms, Glioma, Leukemia, Hairy Cell, Multiple Myeloma, Neoplasms, Gastrointestinal Stromal Tumors, Thyroid Carcinoma, Anaplastic

NCT02404441 2022-08-03

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

Phase 1/2 Completed

319 enrolled 41 charts

BreastDermatologicEndocrineHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

NCT00603941 2020-09-16

A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel

Phase 1/2 Terminated

19 enrolled 13 charts

EndocrineHead & Neck

Neoplasms, Thyroid Carcinoma, Anaplastic

NCT02657369 2019-10-15

A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)

Phase 2 Terminated

34 enrolled 13 charts

EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

NCT00507429 2014-06-09

FACT

Phase 2/3 Terminated

80 enrolled 10 charts

EndocrineHead & Neck

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

Clinical Trials

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel

A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)

FACT